Informations

page personnelle

CV

Hervé Hillaireau est Professeur en Pharmacotechnie et Biopharmacie à l’Université Paris-Sud. Il enseigne la Pharmacie galénique à la Faculté de Pharmacie et effectue ses recherches en ingénierie particulaire et cellulaire à visée thérapeutique dans le groupe d’Elias Fattal au sein de l’Institut Galien Paris-Sud. Ses travaux portent sur la conception de nanovecteurs d’acides nucléiques et d’analogues nucléosidiques/nucléotiques à activité antivirale et anticancéreuse, la fonctionnalisation de surface de nanovecteurs, ainsi que sur l’évaluation toxicologique des nanoparticules biodégradables.

Hervé Hillaireau is Full Professor in Pharmaceutical Technology at the School of Pharmacy of Université Paris-Sud. His research at Institut Galien Paris-Sud in Elias Fattal’s group relates to the design and the toxicological evaluation of biodegradable nanoparticles as drug nanocarriers, with a focus on: nanocarrier design for nucleoside/nucleotide analogues and nucleic acids applied to anticancer and antiviral therapies; nanocarrier surface functionalization for molecular targeting; toxicological evaluation of biodegradable nanoparticles.

Mots clés

Nanovecteurs, acides nucléiques, analogues nucléos(t)idiques, aptamères, nanotoxicologie

Drug nanocarriers, nucleic acids, nucleos(t)ide analogues, aptamers, nanotoxicology

10 publications majeures

• Alshaer W, Hillaireau H, Vergnaud J, Mura S, Deloménie C, Sauvage F, Ismail S, Fattal E. Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model. J Control Release 2018, 271:98-106. doi
• Ruge C, Hillaireau H, Grabowski N, Beck-Broichsitter M, Cañadas O, Tsapis N, Casals C, Nicolas J, Fattal E. Pulmonary surfactant protein A – mediated enrichment of surface-decorated polymeric nanoparticles in alveolar macrophages. Mol Pharm. 2016, 13(12):4168-4178. doi
• Aragao-Santiago L, Hillaireau H*, Grabowski N, Mura S, Nascimento TL, Dufort S, Coll JL, Tsapis N, Fattal E. Compared in vivo toxicity in mice of lung delivered biodegradable and non biodegradable nanoparticles. Nanotoxicology 2015, 10(3):292-302. doi
• Grabowski N, Hillaireau H, Vergnaud J, Nicolas V, Tsapis N, Kerdine-Romer S, Fattal E. Surface-modified biodegradable nanoparticles’ impact on cytotoxicity and inflammation response on a co-culture of lung epithelial cells and human-like macrophages. J Biomed Nanotechnol. 2016, 12(1):135-146. doi
• Alshaer W, Hillaireau H, Vergnaud J, Ismail S, Fattal E. Functionalizing liposomes with anti-CD44 aptamer for selective targeting of cancer cells. Bioconjugate Chem. 2015, 26(7):1307-1313. doi
• Nascimento TL, Hillaireau H, Noiray M, Bourgaux C, Arpicco S, Pehau-Arnaudet G, Taverna M, Cosco D, Tsapis N, Fattal E. Supramolecular Organization and siRNA Binding of Hyaluronic Acid- 2 Coated Lipoplexes for Targeted Delivery to the CD44 Receptor. Langmuir 2015, 31(41):11186-11194. doi
• Giacalone G, Hillaireau H, Capiau P, Chacun H, Reynaud F, Fattal E. Stabilization and cellular delivery of chitosan-polyphosphate nanoparticles by incorporation of iron. J Control Release. 2014, 194:211-219. doi
• Hillaireau H, Dereuddre-Bosquet N, Skanji R, Bekkara-Aounallah F, Caron J, Lepe^tre S, Argote S, Bauduin L, Yousfi R, Rogez-Kreuz C, Desmae¨le D, Rousseau B, Gref R, Andrieux K, Clayette P, Couvreur P. Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies. Biomaterials. 2013, 34(20):4831-4838. doi
• Giacalone G, Bochot A, Fattal E, Hillaireau H*. Drug-Induced Nanocarrier Assembly as a Strategy for the Cellular Delivery of Nucleotides and Nucleotide Analogues. Biomacromolecules. 2013, 14(3):737-742. doi
• Hillaireau H, Couvreur P. Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci. 2009, 66(17):2873-2896. doi